The FDA has called on Johnson & Johnson, the manufacturer of Ditropan, to publish a stronger warning regarding the potential hallucinogenic risks for children and the elderly. Ditropan is used for bladder problems. The drug, also known as oxybutynin, already lists insomnia, nervousness, confusion and other central nervous system risks on its label, but FDA staff reviewers said more explicit cautions are needed.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.